Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Generics Could Cut Costs of HIV Treatment

The U.S. could save nearly $1 billion in the first year that generic anti-HIV drugs become available to American patients, researchers reported.

Published
15 January 2013
From
MedPage Today HIV/AIDS
Achillion Continues To Make Significant Strides In The Fight Against Hepatitis C

Financial analysis of the Achillion hepatitis C drug pipeline; "Achillion is making considerable strides in terms of four drugs currently in its pipeline," Seeking Alpha comments.

Published
15 January 2013
From
Seeking Alpha
Nigerian texters to take on the drug counterfeiters

Can you tell which is the fake drug for sale in Nigeria?

Published
11 January 2013
From
BBC Health
Glaxo Says No Plan for Viiv Spinoff ‘at the Moment’

GlaxoSmithKline Plc (GSK) has no plans “at the moment” to spin off its ViiV Healthcare Ltd. unit that is developing drugs to treat HIV, said Patrick Vallance, Glaxo’s president of pharmaceuticals research and development.

Published
11 January 2013
From
Bloomberg
Idenix May Drop Delayed Hepatitis C Drug for New Versions

Idenix Pharmaceuticals Inc. (IDIX), a developer of hepatitis C drugs, may shelve experimental treatments currently on hold by U.S. regulators and focus on different versions, Chief Executive Officer Ron Renaud said.

Published
10 January 2013
From
Businessweek
Gilead Provides Update on Hepatitis C Development Programs

Sustained Virologic Response Achieved with Oral Regimen of Sofosbuvir, GS-5885 and Ribavirin in 9/9 Null Responder Genotype 1 Hepatitis C Patients; Second Phase 3 Study Evaluating Fixed-dose Combination of Sofosbuvir and GS-5885 to Begin Later this Month.

Published
08 January 2013
From
Gilead press release
Achillion Reports Interim Results on ACH-3102

Enrollment completed in pilot Phase 2a study of ACH-3102 and ribavirin for genotype 1b CC patients; up to 12 weeks of once daily ACH-3102 appears safe and well tolerated with no on-treatment virologic breakthrough observed to date.

Published
08 January 2013
From
Achillion press release
Thai-EU Free Trade Agreement Raises Alarm for People With AIDS

Days before leaders of the European Union (EU) arrived in Norway to collect this year’s Nobel Peace prize, Thai public health activists sent a letter to the northern powerhouse, warning that the EU’s 2012 accolades face a credibility test in this Southeast Asian country.

Published
03 January 2013
From
Inter Press Service
Medivir announces phase III data for Simeprevir demonstrating efficacy and safety in genotype 1 hepatitis C patients

Simeprevir achieved SVR12 rates (viral cure) of 79% to 81% in the three pivotal phase III trials QUEST-1, QUEST-2 and PROMISE in genotype 1 hepatitis C patients. The overall results demonstrate that simeprevir is safe and well tolerated with a safety profile of the simeprevir treatment arms similar to the placebo control. A majority of the patients, 85-93%, were able to stop all treatment after 24 weeks.

Published
20 December 2012
From
Medivir press release
Industry Funding Changes Study Results, Research Shows

Drugs and medical devices tend to appear more beneficial in scientific papers if they were manufactured by the company that sponsored the study, showing that who pays for the clinical trial has a direct impact on the reported outcome, according to a new analysis by researchers at UCSF and the Cochrane Collaboration.

Published
20 December 2012
From
University of California press release

Filter by country